



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 1/04 (2006.01)
C07K 16/24 (2006.01)

(21) International Application Number:

PCT/US2022/016841

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/150,825	18 February 2021 (18.02.2021)	US
63/180,892	28 April 2021 (28.04.2021)	US
63/226,037	27 July 2021 (27.07.2021)	US
63/285,781	03 December 2021 (03.12.2021)	US

(71) Applicants: **PROMETHEUS BIOSCIENCES, INC.**

[US/US]; 9410 Carroll Park Drive, San Diego, California 92121 (US). **CEDARS-SINAI MEDICAL CENTER** [US/US]; 8700 Beverly Blvd., Los Angeles, California 90048 (US).

(72) Inventors: **LUO, Allison**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **OTSUKI, Lauren**; 9410


Carroll Park Drive, San Diego, California 92121 (US). **MANNING, Mark**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **PAYNE, Robert**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **LAURENT, Olivier**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **BILSBOROUGH, Janine**; 8700 Beverly Blvd., Los Angeles, California 90048 (US). **HENKLE, Bradley**; 8700 Beverly Blvd., Los Angeles, California 90048 (US). **TARGAN, Stephan R.**; 8700 Beverly Blvd., Los Angeles, California 90048 (US).

(74) Agent: **UMPIERRE, Alicia**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF

FIG. 23A



(57) Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*